Cargando…
Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
SIMPLE SUMMARY: Immunotherapies are modern treatment modalities, giving hope for improvements of frozen cure rates in many childhood malignancies. More intensive cytotoxic chemotherapy cycles didn’t improve cure rates, only increase number of adverse events. Blinatumomab, a bispecific CD3/CD19 antib...
Autores principales: | Pawinska-Wasikowska, Katarzyna, Wieczorek, Aleksandra, Balwierz, Walentyna, Bukowska-Strakova, Karolina, Surman, Marta, Skoczen, Szymon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773605/ https://www.ncbi.nlm.nih.gov/pubmed/35053619 http://dx.doi.org/10.3390/cancers14020458 |
Ejemplares similares
-
Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022) -
Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report
por: Pawińska-Wa̧sikowska, Katarzyna, et al.
Publicado: (2020) -
Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023) -
Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023) -
Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome
por: Czogala, Malgorzata, et al.
Publicado: (2022)